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Abstract
We aimed to describe clinical and diagnostic features of vertebral osteomyelitis for differential diagnosis and treatment. This is a prospective
observational study performed between 2002 and 2012 in Ankara Numune Education and Research Hospital in Ankara, Turkey. All the
patients with vertebral osteomyelitis were followed for from 6 months to 3 years. In total, 214 patients were included in the study, 113 out
of 214 (53%) were female. Out of 214 patients, 96 (45%) had brucellar vertebral osteomyelitis (BVO), 63 (29%) had tuberculous vertebral
osteomyelitis (TVO), and 55 (26%) had pyogenic vertebral osteomyelitis (PVO). Mean number of days between onset of symptoms and
establishment of diagnosis was greater with the patients with TVO (266 days) than BVO (115 days) or PVO (151 days, p <0.001). In blood
cultures, Brucella spp. were isolated from 35 of 96 BVO patients (35%). Among 55 PVO patients, the aetiological agent was isolated in 11
(20%) patients. For tuberculin skin test >15 mm, sensitivity was 0.66, speciﬁcity was 0.97, positive predictive value was 0.89, negative
predictive value was 0.88, and receiver operating characteristics area was 0.8. Tuberculous and brucellar vertebral osteomyelitis remained
the leading causes of vertebral osteomyelitis with delayed diagnosis. In differential diagnosis of vertebral osteomyelitis, consumption of
unpasteurized cheese, dealing with husbandry, sweating, arthralgia, hepatomegaly, elevated alanine transaminase, and lumbar involvement in
magnetic resonance imaging were found to be predictors of BVO, thoracic involvement in magnetic resonance imaging and tuberculin skin
test > 15 mm were found to be predictors of TVO, and history of spinal surgery and leucocytosis were found to be predictors of PVO.
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Introduction
Vertebral osteomyelitis (VO) is a compelling clinical entity for
clinicians, because of its insidious start and indolent course,
which make diagnosis difﬁcult. As a consequence, patients often
develop destructive lesions or neurological complications
related to compression of the spinal cord or its roots [1].
Vertebral osteomyelitis is an infrequent infection; however, the
incidence is increasing because of the growing number of older
patients and chronic diseases [1]. In many reports VO was
grouped as brucellar (BVO), tuberculous (TVO) and pyogenic
(PVO) [1,2]. Some studies reported only one clinical entity [3];
however, comparable studies are necessary for differential
diagnosis of these disease entities for management of patients.
Diagnostic studies of VO differ according to the prevalence
of these diseases. This study was performed in Turkey, where
brucellosis and tuberculosis are more common than in
European and North American countries. By this prospective
study, we aimed to describe clinical and diagnostic features of
VO for differential diagnosis and treatment.
Materials and Methods
This is a prospective observational study performed between
2002 and 2012 in Ankara Numune Education and Research
Hospital in Ankara, Turkey. Diagnosis of VO was made
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according to clinical, radiological and microbiological criteria,
which were deﬁned previously [4,5]. The diagnostic algorithm
was performed according to (i) clinical symptoms suggestive of
VO, (ii) laboratory abnormalities—complete white blood cell
count, erythrocyte sedimentation rate, C-reactive protein
level, Brucella tube agglutination test of serum and/or cere-
brospinal ﬂuid, tuberculin skin test (TST), (iii) abnormal
magnetic resonance imaging (MRI) or computed tomography
scan features compatible with infection of the spine, (iv)
isolation of the causative microorganism, typical histological
pattern from percutaneous disc or epidural abscess puncture
or biopsy, and speciﬁc tests for microorganisms.
Patients were included if there was illness compatible with
vertebral infection and evidence of spinal involvement from
imaging. Deﬁnite diagnosis of TVO was considered when
Mycobacterium tuberculosis was isolated from a sample of
vertebral, paravertebral or epidural tissue or from a psoas
abscess. Probable TVO diagnosis was considered when caseat-
ing granulomas, with or without acid-fast bacilli, PCR positivity
in a vertebral biopsy and TST positivity were found, or when
M. tuberculosiswas isolated from another focus of infection such
as sputum, urine and cerebrospinal ﬂuid. Presumptive diagnosis
of TVO was considered when positive ﬁndings by imaging, plus
positive TST, and no response to non-speciﬁc antibiotics but
response to anti-tuberculosis treatment were reported. Def-
inite BVOwas considered when Brucella spp. were isolated from
a sample of vertebral, paravertebral or epidural tissue or from a
psoas abscess, from blood or other body ﬂuid or tissue
specimens, or when Brucella standard tube agglutination of >1/
160 was found in addition to clinical ﬁndings compatible with
VO. Deﬁnite PVO was considered when a microorganism was
isolated from the involved vertebra, intervertebral disc space,
or paravertebral or epidural abscesses. Probable PVO was
considered when the results of at least two blood cultures were
positive during a compatible illness. Presumptive PVO was
considered when an organism was isolated from urine, stool
and wound, if a sinus tract was detected in contiguity with the
vertebral lesions, if there was a history of vertebral surgery, and
if empiric antibiotic therapy was successful. For each disease
entity, the other two entities were ruled out. All the patients
with VOwere followed for from 6 months to 3 years. Informed
consent was obtained from patients.
Statistical analysis
Chi-square test was used for comparison of categorical
variables and t-test was used for comparison of continuous
variables. Multivariate analysis was performed for detection of
the predictors of each disease category separately. Indepen-
dent variables were selected from the statistically signiﬁcant
variables listed in Tables 1 and 2. In multivariate analysis for
the predictors of BVO, consumption of unpasteurized cheese,
dealing with husbandry, sweating, arthralgia, hepatomegaly,
elevated alanine transaminase, and lumbar involvement in MRI
were included in the regression model. In multivariate analysis
for prediction of TVO, thoracic involvement in MRI and TST
>15 mm were included in the regression model. In multivariate
analysis for prediction of PVO, history of spinal surgery and
leucocytosis were included in the model. A backward selection
process was run. In analysis, STATA version 11 (StatCorp,
College Station, TX, USA) was used, and statistical signiﬁcance
was set as p <0.005.
Results
In total, 214 patients were included in the study, 113 (53%)
were female. Out of 214 patients, 96 (45%) had BVO, 63 (29%)
had TVO and 55 (26%) had PVO. The mean age of the patients
with TVO was lower than that of the patients with BVO and
PVO (43 versus 53 and 53 years, p <0.001, Table 1). Con-
sumption of fresh cheese and dealing with husbandry, and
being a farmer were more commonly reported among the
patients with BVO (p <0.001, Table 1). Diabetes mellitus was
more common among patients with PVO (33%) than patients
with BVO (15%) or TVO (33%, p 0.028, Table 1). The history
of spinal surgery was more common among the patients with
PVO (64%) than the patients with BVO (11%) or TVO (13%,
p <0.001, Table 1).
Fever as a symptom or sign was not statistically different
among the three groups; however, sweating was more
common (81%) among the patients with BVO (p <0.001,
Table 1). The history of upper back pain and cervical pain were
more common in patients with TVO (p 0.016 and p 0.014,
respectively) than in those with BVO and PVO. However, leg
pain was more common among patients with PVO (p 0.003,
Table 1). Urinary and defecation incontinence were reported
in two patients with PVO and one patient with BVO.
Haemoptysis was reported in one of the patients with TVO.
Among 96 patients with BVO, 23 (24%) were diagnosed as
having neurobrucellosis.
Among TVO cases, 25% had deﬁnite diagnosis, 21%
probable diagnosis, and so 46% had deﬁnite or probable
diagnosis. Among BVO cases, all were considered to be
deﬁnite diagnoses, whereas among PVO cases, 58% were
diagnosed as deﬁnite or probable (Table 3). Distribution of
bacterial agents were, six methicillin-sensitive Staphylococcus
aureus, one methicillin-resistant S. aureus, two methicil-
lin-resistant coagulase-negative S. aureus and two Escherichia
coli. In urinary culture, a total of 11 aetiological agents were
isolated, one Salmonella Virchow, seven E. coli, (four
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extended-spectrum b-lactamase positive), one Klebsiella spp.,
one Enterococcus faecalis, one methicillin-resistant Staphylococ-
cus epidermidis. In stool culture, in one patient Salmonella
Group C was isolated. In decubitis culture among the patients
with PVO, in two patients Klebsiella spp., Acinetobacter and
Pseudomonas spp. were isolated.
For TST >15 mm, sensitivity was 0.66, speciﬁcity was 0.97,
positive predictive value was 0.89, negative predictive value
was 0.88, and receiver operating characteristic area was 0.8.
The same parameters for TST >10 mm were 0.93, 075, 0.62,
0.96, and receiver operating characteristic area was 0.82. In
multivariate analysis, TST >15 mm predicted TVO signiﬁcantly
(OR = 16, 95% CI 7.32–37.86; p <0.001, Table 4).
Among the patients with TVO, cervical involvement
(p 0.023) and thoracic involvement (p 0.018) were more
common than in the other patients. Among the patients with
BVO, lumbar involvement was signiﬁcantly more common than
in the other patients (p <0.001). Discitis was detected in 86
(90%) patients with BVO, 45 (71%) patients with TVO, and 43
(78%) patients with PVO (p 0.013). Abscess was detected in
78 (81%) patients with BVO, 52 (83%) with TVO and 49 (89%)
with PVO (p 0.438). Psoas abscess was detected in 13 of 96
TABLE 1. Demographic and epide-
miological features
Brucella vertebral
osteomyelitis
n = 96 (%)
Tuberculous vertebral
osteomyelitis
n = 63 (%)
Pyogenic vertebral
osteomyelitis
n = 55 (%) p
Female gender 57 (59) 28 (44) 28 (51) 0.173
Mean age (SD; min–max) 53 (16; 13–81) 43 (18; 14–77) 53 (15; 20–83) <0.001
Consumption of fresh cheese 81 (84) 17 (27) 18 (33) <0.001
Dealing with husbandry 62 (65) 8 (13) 9 (16) <0.001
History of spinal surgery 11 (11) 8 (13) 35 (64) <0.001
Diabetes mellitus 14 (15) 12 (19) 18 (33) 0.028
Mean days between onset of
symptoms and establishment
of diagnosis
115 (SD 98,
min 10, max 365)
266 (SD 43, min 7,
max 1460)
151 (SD 264, min 10,
max 1800)
<0.001
Symptoms
Fever 67 (70) 33 (52) 37 (67) 0.069
Sweating 78 (81) 36 (57) 24 (44) <0.001
Loss of appetite 66 (69) 40 (63) 26 (47) 0.031
Weight loss 59 (61) 36 (57) 19 (35) 0.005
Headache 27 (28) 13 (21) 8 (15) 0.144
Cough 5 (5) 6 (10) 4 (7) 0.578
Low back pain 90 (94) 55 (87) 52 (95) 0.248
Upper back pain 14 (15) 20 (32) 8 (15) 0.016
Cervical pain 3 (3) 10 (16) 4 (7) 0.014
Leg pain 47 (49) 33 (53) 42 (76) 0.003
Inability to walk 21 (22) 16 (45) 26 (47) 0.003
Arthralgia 29 (30) 4 (6) 1 (2) <0.001
Physical examination
Body temperature >38°C 24 (25) 13 (21) 14 (25) 0.776
Hepatomegaly 39 (41) 8 (13) 10 (18) <0.001
Splenomegaly 15 (16) 1 (2) 2 (3) 0.003
Orchitis 3 (3) 0 (0) 0 (0) NA
Neck rigidity 2 (2) 2 (3) 1 (2) 0.867
Arthritis 5 (5) 2 (3) 0 (2) 0.223
TABLE 2. Laboratory ﬁndings
Brucella vertebral
osteomyelitis
n = 96 (%)
Tuberculous
vertebral
osteomyelitis
n = 63 (%)
Pyogenic
vertebral
osteomyelitis
n = 55 (%) p
Leucocyte count
<4000/mm3 8 (8) 5 (8) 0 (0) <0.001
4000–10 000/mm3 74 (77) 44 (70) 29 (53)
>10 000/mm3 14 (15) 14 (22) 26 (47)
Polymorphonuclear leucocytes (>75%) 10 (10) 20 (32) 20 (36) <0.001
Lymphocytes (>45%) 14 (15) 1 (2) 0 (0) <0.001
Monocytes (>9%) 26 (27) 16 (25) 7 (13) 0.111
Platelet <150 000/mm3 3 (3) 4 (6) 1 (2) 0.395
Haemoglobin <10 g/L 23 (24) 19 (30) 24 (44) 0.041
Haematocrit <35% 41 (43) 30 (48) 37 (67) 0.013
Median erythrocyte sedimentation rate 50 44 70 <0.001
Median C-reactive protein 29 29 70 0.002
Elevated alanine transaminase >40 U/L 26 (27) 7 (11) 10 (18) 0.045
Elevated aspartate transaminase >40 U/L 22 (23) 13 (21) 9 (16) 0.631
c-glutamyl transferase >50 U 46 (48) 19 (30) 22 (40) 0.083
Albumin 19 (20) 19 (30) 24 (44) 0.009
Globulin 52 (55) 31 (50) 30 (55) 0.825
Rheumatoid factor 8 (8) 2 (3) 2 (4) 0.293
TST ≥ 10 mm 23 (24) 54 (86) 26 (47) <0.001
TST ≥ 15 mm 7 (7) 34 (54) 3 (5) <0.001
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patients with BVO (13.5%), 18 of 63 patients with TVO
(28.5%), and 12 of 55 patients with PVO (22%, Table 5).
Median days of non-speciﬁc antibiotic therapy before diag-
nosis of tuberculosis were 35 days (10–351). Median days of
parenteral antibiotic therapy for BVO were 21 days (5–31), for
TVO 27 days (10–169) and for PVO 35 days (14–563). Median
days of oral antibiotic therapy for BVO were 180 days (7–561),
for TVO 360 days (60–720) and for PVO 144 days (14–420).
In multivariate analysis, consumption of fresh cheese,
dealing with husbandry, sweating, arthralgia, hepatomegaly,
alanine transaminase >40 IU, lumbar involvement in MRI were
found to be predictive for BVO; thoracic involvement in MRI
and TST >15 mm were found to be predictive for TVO;
history of spinal surgery and leucocytosis were found to be
predictive for PVO (Table 4).
Discussion
Studies from northern Europe and North America reported
pyogenic VO; however, the aetiologies of VO are not limited to
pyogenic microorganisms in many other countries. In Turkey, as
a country between Asia and Europe, the aetiological list of VO
includes Brucella spp. and M. tuberculosis spp., as well. Speciﬁc
microorganisms can be identiﬁed in fewer than half of the
patients [6,7]. Hence, case management is made by synthesis of
data on epidemiological, clinical, laboratory, and imaging studies.
As one of the strong parts of this study, multivariate analysis was
performed for each category of disease entity.
Mean number of days between onset of symptoms and
establishment of diagnosis was greater among the patients with
TVO (266 days) than the patients with BVO (115 days) or
PVO (151 days, p <0.001, Table 1). This time interval was
reported to be 2–12 months in previous reports [3,8,9]. Such
a long period of time before diagnosis could be related to the
low frequency of disease and non-speciﬁc nature of the
symptoms, such as low back pain.
Fever as a symptom was detected in 50–70% of our
patients, with the lowest rate among patients with TVO,
although there was no statistical signiﬁcance among the three
groups (Table 1). Body temperature >38°C was detected in
around one-quarter of the patients (Table 1). In previous
studies, fever was reported in only about half of patients
[10,11], and, fever was reported as less common in patients
with TBO [12]; however, in our multivariate analysis sweating
was found to be 3.2 times more common (OR = 3.2, 95% CI
1.41–7.18; p 0.005) among the patients with BVO than TVO
or PVO (Table 4). Back or neck pain is common [3], but up to
15% of patients may be pain free [10]. In our study, low back
pain was highly common among all patient groups, whereas
upper back and cervical pain were found to be signiﬁcantly
more common among patients with TVO (Table 1), which was
related to thoracic involvement in TVO (Table 4). In our
study, leg pain was signiﬁcantly more common among patients
with PVO than those with BVO or TVO (Table 1). This could
TABLE 3. Serological and bacteriological ﬁndings
Brucella vertebral osteomyelitis n = 96 (%)
Culture 35 (35)
Blood 35 (35)
Cerebrospinal ﬂuid 1
Synovial ﬂuid 1
Serological tests
Serum tube agglutination (STA) ≥100 95 (99)
Median STA 800
STA with CoomBVO (STA) ≥100 95 (99)
Median STA with CoomBVO 400
Tuberculosis vertebral osteomyelitis n = 63 (%)
Culture 16 (25)
Acid fast stain 11 (6)
Pathological ﬁndings speciﬁc for
tuberculosis (caseous, granulomatous)
10 (6)
Culture negative PCR positive 2
TST ≥15 34 (54)
Pyogen vertebral osteomyelitis n = 55 (%)
Culture
Blood 11 (20%)
Surgical material 14
Urine 11
Stool 1
TABLE 4. Multivariate analysis for brucellar, tuberculous,
and purulent vertebral osteomyelitis among 214 patients
OR 95% CI p
Brucellar vertebral osteomyelitis
Consumption of fresh cheese 5.4 2.22–12.9 <0.001
Dealing with husbandry 4.4 1.82–10.93 0.001
Sweating 3.2 1.41–7.18 0.005
Arthralgia 6.2 1.72–22.24 0.005
Hepatomegaly 3 1.08–6.65 0.033
Alanine transaminase >40 IU 3.1 1.25–7.44 0.014
Lumbar involvement in MRI 3 1.17–8.3 0.023
Tuberculous vertebral osteomyelitis
Thoracic involvement in MRI 2.5 1.02–6.25 0.044
TST > 15 mm 16 7.32–37.86 <0.001
Pyogenic vertebral osteomyelitis
History of spinal surgery 14.7 6.54–32.89 <0.001
Leucocytosis 5.4 2.43–12.14 <0.001
TABLE 5. Magnetic resonance image ﬁndings in patients
with brucellar, tuberculous, and purulent vertebral osteomy-
elitis
Brucellar
vertebral
osteomyelitis
n = 96 (%)
Tuberculous
vertebral
osteomyelitis
n = 63 (%)
Pyogenic
vertebral
osteomyelitis
n = 55 (%)
Involved vertebra levels
Cervical 4 (4) 7 (11) 1 (2)
Thoracic 8 (8) 15 (24) 9 (16)
Thoracolumbar 7 (6) 11 (17) 8 (15)
Lumbar 58 (60) 23 (37) 23 (42)
Lumbosacral 19 (20) 7 (11) 14 (25)
Localization of abscess
Paravertebral 30 (32) 15 (24) 17 (31)
Epidural 19 (20) 7 (11) 7 (13)
Epidural + paravertebral 15 (16) 12 (19) 13 (24)
Psoas 2 (8) 8 (13) 0 (0)
Paravertebral + psoas 6 (6) 6 (10) 4 (7)
Paravertebral +
epidural + psoas
5 (5) 4 (6) 8 (15)
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1055–1060
1058 Clinical Microbiology and Infection, Volume 20 Number 10, October 2014 CMI
be related to more frequent involvement of the epidural space
that was detected in MRI. Epidural involvement was detected
more commonly among patients with PVO (51%) than patients
with BVO (40%) or TVO (36%). Twenty-four percent of
patients with BVO were diagnosed as having neurobrucellosis.
Among the inﬂammatory markers, erythrocyte sedimenta-
tion rate and C-reactive protein are sensitive markers for
infection but lack speciﬁcity [10], leucocytosis is occasionally
present [13]. In our study, erythrocyte sedimentation rate and
C-reactive protein were found to be signiﬁcantly higher among
patients with PVO than those with BVO or TVO (Table 1).
These ﬁndings were in parallel with another report; however,
in that report C-reactive protein elevation in the PVO group
was not found to be statistically signiﬁcant [1]. The leucocyte
count was reported to be one of the least useful among the
inﬂammatory markers [10]; however, in multivariate analysis
we detected leucocytosis as one of the signiﬁcant predictors of
PVO (OR = 5.4, 95% CI 2.43–12.14; p <0.001, Table 4).
In our study, the most common aetiological agent in PVO
was Staphylococcus spp. In previous reports, Staphylococcus spp.
were reported as the most common causative agent, varying
from 20% to 84% [8,10,14–16], whereas Gram-negative rods
were reported as causative agents in 7–33% of patients with
PVO [13,15,16]. In our study, the most common agents were
E. coli, Klebsiella spp. and Salmonella spp. These microorganisms
were associated with urinary or gastrointestinal tract infec-
tions. The Wright agglutination test was useful in diagnosis of
BVO; Wright agglutination was positive in 99% of patients with
BVO, whereas the bacteria were isolated in only 39% of
patients with BVO.
Tuberculin skin test sensitivity and speciﬁcity is inﬂuenced
by the cut-off used. A higher cut-off will result in a higher
speciﬁcity and a lower sensitivity for M. tuberculosis infection
[17]. In our study, in multivariate analysis, TST >15 mm
predicted TVO signiﬁcantly (OR = 16, 95% CI 7.32–37.86;
p < 0.001, Table 4). For TST >15 mm, sensitivity was 0.66,
speciﬁcity was 0.97, positive predictive value was 0.89, negative
predictive value was 0.88, and receiver operating characteristic
area was 0.8. In regions with higher prevalence of tuberculosis,
using TST with 15-mm cut-off could be useful in diagnosis of
tuberculosis.
Magnetic resonance imaging is considered the modality of
choice for the radiological diagnosis of VO [5,18]. It has a
reported sensitivity of 96%, speciﬁcity of 93% and accuracy of
94% [10]. In multivariate analyses, lumbar level involvement
was found to be signiﬁcantly more common among patients
with BVO; however, thoracic level involvement was found to
be more common among patients with TVO (Table 4).
Another study reported signiﬁcance of thoracic level involve-
ment for patients with TVO [1]. More common thoracic
involvement in patients with TVO could be explained by more
frequent involvement of lymph nodes and the pleura in
pulmonary tuberculosis, from where bacteria can reach the
vertebral bone through the lymphatic route. In patients with
BVO, lumbar involvement was reported as the most common
location [19]. Discitis was found to be more common among
patients with BVO, but presence of psoas abscess was more
common among patients with TVO (Table 5). Previous studies
reported the relatively higher frequency of psoas abscesses
among patients with TVO, by noting vertebral, intestinal or
genitourinary infections as the potential source [2,20].
There is no standard choice of agents and standard duration
for VO, yet. Median days of non-speciﬁc antibiotic therapy
before diagnosis of tuberculosis were 35 days (10–351).
Median days of parenteral antibiotic therapy for BVO were
21 days (5–31), for TVO 27 days (10–169), and for PVO
35 days (14–563). Median days of oral antibiotic therapy for
BVO were 180 days (7–561), for TVO 360 days (60–720), and
for PVO 144 days (14–420). In treatment of BVO, rifampicin
plus doxycycline or ceftriaxone were given for 6 weeks to
6 months. In treatment of TVO, four drugs were given for the
ﬁrst 2 months of therapy, followed by two drugs for
10 months. In treatment of PVO, in addition to glycopeptides,
ﬂuoroquinolones, or a b-lactam antibiotic was given. Duration
of therapy was adjusted according to the clinical condition and
laboratory ﬁndings of the patient. In BVO, 85% of the patients
received oral therapy, whereas additional surgical therapy was
performed in TVO (56%) and PVO (47%, Table 6). In 73% of
TABLE 6. Treatment modalities for
the patients with vertebral osteo-
myelitis
Brucellar
vertebral
osteomyelitis
n = 96 (%)
Tuberculous
vertebral
osteomyelitis
n = 63 (%)
Pyogenic
vertebral
osteomyelitis
n = 55 (%) p
Medical treatment 85 (89) 19 (30) 24 (44) <0.001
Medical + percutaneous drainage
of abscess
5 (5) 5 (7) 1 (2)
Medical + surgical 6 (6) 35 (56) 27 (47)
Medical + surgical + percutaneous
drainage of abscess
0 4 (6) 3 (5)
Number of surgical operations
Once 3 (3) 32 (51) 22 (40) <0.001
Twice 3 (3) 3 (5) 3 (5)
Three or more 0 (0) 4 (6) 4 (7)
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patients with BVO, 84% of patients with TVO and 62% of
patients with PVO were cured. Overall, 25% of the patients
were lost to follow up. One patient with BVO (1%), and two
patients with PVO (4%) relapsed.
Conclusion
Tuberculous and brucellar VO remained the leading causes
of VO with delayed diagnosis. In differential diagnosis of VO,
consumption of fresh cheese, dealing with husbandry,
sweating, arthralgia, hepatomegaly, elevated alanine transam-
inase and lumbar involvement in MRI were found to be
predictors of BVO, thoracic involvement in MRI and TST
>15 mm were found to be predictors of TVO, and history
of spinal surgery and leucocytosis were found to be
predictors of PVO.
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